What's Happening?
AstraZeneca's IMFINZI (durvalumab) has been approved by the U.S. Food and Drug Administration (FDA) for use in combination with Bacillus Calmette-Guérin (BCG) therapy for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). This
approval is based on the results of the POTOMAC Phase III trial, which demonstrated a 32% reduction in the risk of disease recurrence, progression, or death when IMFINZI was added to BCG therapy compared to BCG alone. The trial results were presented at the European Society for Medical Oncology Congress 2025 and published in The Lancet. This marks the first new therapy approved in over 30 years for this patient group.
Why It's Important?
The approval of IMFINZI in combination with BCG represents a significant advancement in the treatment of high-risk NMIBC, a condition with a high rate of recurrence and progression. This new treatment option could reduce the need for repeated surgical procedures and potentially prevent the progression to more advanced disease stages, which often require bladder removal. The approval provides a new hope for patients and could improve their quality of life by offering a less invasive treatment option with sustained disease-free survival benefits.
What's Next?
Following the FDA approval, AstraZeneca plans to submit regulatory applications in other regions, including the European Union and Japan. The company is also conducting further studies to explore the use of IMFINZI in other cancer types and stages. The oncology community will be watching closely to see how this new treatment impacts patient outcomes and whether it becomes a new standard of care for high-risk NMIBC.
